Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.

Created on 04 Jul 2026

Authors

Yue Li, Chen Chen, HaiLin Liu, ZhenFa Zhang, ChangLi Wang

Published in

Respiratory research. Jul 03, 2026. Epub Jul 03, 2026.

Abstract

Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality, often driven by the hyperactivation of cell cycle and DNA repair pathways. While genomic alterations in these pathways are well-documented, the role of RNA epigenetics in orchestrating these oncogenic signals remains poorly understood. Here, we identify a hierarchical signaling axis driven by the RNA methyltransferase NSUN2 that fuels LUAD progression. We demonstrate that NSUN2 is frequently amplified and overexpressed in LUAD, where it correlates with advanced disease stage and poor patient survival. Mechanistically, NSUN2 catalyzes 5-methylcytosine (m5C) modification of the E2F1 3'-untranslated region (3'-UTR). This modification, recognized by the reader protein YBX1, enhances the translational efficiency of E2F1 transcripts. The resulting accumulation of E2F1 transcriptionally activates the DNA translocase RAD54L, which we redefine as a proactive oncogenic effector essential for cell proliferation, invasion, and in vivo tumorigenesis. Integrated multi-omics and rescue experiments confirm that the NSUN2-mediated translational induction of E2F1 is a prerequisite for RAD54L-driven malignancy. Our findings uncover a novel epitranscriptomic-transcriptional regulatory cascade, establishing the NSUN2-E2F1-RAD54L axis as a critical driver of LUAD and a promising target for therapeutic intervention.

PMID:
42399962
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement